This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through October 6, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Here's Why Philip Morris (PM) is a Strong Growth Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Altria Returns $4 Billion to Shareholders in First Half of 2025
by Zacks Equity Research
MO has returned more than $4 billion to its shareholders in early 2025, fueled by strong dividends, buybacks and a solid balance sheet.
Hain Celestial Q4 Earnings Coming Up: What to Expect From HAIN Stock?
by Zacks Equity Research
Hain Celestial's Q4 sales and profit are likely to have been pressured by soft demand in North America, underperforming promotions and tough competition.
Mo's Smoke-Free Vision vs. Cigarette Declines: Is Transition on Track?
by Zacks Equity Research
Altria shows cigarette volumes sliding while on! nicotine pouches surge in the second quarter, spotlighting the gradual shift toward smoke-free growth.
The Zacks Analyst Blog Highlights Microsoft, Amazon.com, Philip Morris International, Preformed Line Products and Security Federal
by Zacks Equity Research
Zacks spotlights Microsoft, Amazon, and Philip Morris, alongside microcaps Preformed Line Products and Security Federal, with updates on AI, smoke-free growth, and small-cap resilience.
Top Analyst Reports for Microsoft, Amazon.com & Philip Morris
by Mark Vickery
Microsoft, Amazon.com and Philip Morris headline fresh analyst reports highlighting AI, cloud, and smoke-free growth momentum.
Can on! Help Altria Capture More of the Booming Pouch Market?
by Zacks Equity Research
MO's on! shipments jumped 26.5% in the second quarter, lifting its U.S. pouch share as marketing and earnings momentum intensify in a fast-growing market.
Altria (MO) Up 7.2% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Altria (MO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why Philip Morris (PM) is a Strong Growth Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Philip Morris Transformation Accelerates With IQOS and ZYN Growth
by Zacks Equity Research
PM's second-quarter results show smoke-free gains lifting revenues and profit, even as cigarette volumes continue to decline.
What's Driving Altria Group's Growth in OCI for Smokeables?
by Zacks Equity Research
MO's smokeable margins jumped 2.9 percentage points to 64.5% as pricing power and cost cuts offset sharp volume declines.
Altria vs. Philip Morris: Which Stock Smokes Out Better Returns?
by Swati Prasad
MO and PM battle for investor favor as smoke-free gains, pricing power and earnings growth reshape their outlooks.
Altria Bets on Pricing: A Cushion Against Falling Volumes?
by Zacks Equity Research
MO uses pricing strength to cushion profits against steep drops in cigarette volumes.
Should You Buy Altria Stock as it Hits a New 52-Week High?
by Swati Prasad
MO hits a 52-week high on earnings growth, oral tobacco gains and rising investor confidence in its long-term strategy.
Philip Morris (PM) Up 5% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Philip Morris (PM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
PM Stock Trades at Premium Value: Should You Buy, Hold or Sell?
by Swati Prasad
Philip Morris' smoke-free growth is strong, but cigarette declines and a premium valuation urge cautious investment moves.
Philip Morris Aims for $2B Cost Savings by 2026: How Close Is It?
by Zacks Equity Research
PM has already captured $1.2 billion in savings by mid-2025, keeping it on track to hit its $2 billion cost-cutting target by 2026.
The Zacks Analyst Blog Highlights Broadcom, Philip Morris International and Novo Nordisk
by Zacks Equity Research
Broadcom rides AI growth and VMware integration, Philip Morris pushes smoke-free transition, while Novo Nordisk grapples with Wegovy knockoffs and intense competition.
Top Stock Reports for Broadcom, Philip Morris & Novo Nordisk
by Mark Vickery
Broadcom, Philip Morris, and Novo Nordisk face contrasting outlooks as AI growth, smoke-free expansion, and obesity drug hurdles shape performance.
How to Boost Your Portfolio with Top Consumer Staples Stocks Set to Beat Earnings
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Philip Morris' ILUMA Rollout: Will It Power H2 Volume Growth? (Revised)
by Swati Prasad
ILUMA's broader launch and expanded consumables range are contributing to PM's heated tobacco growth in 2025.
Philip Morris' ILUMA Rollout: Will It Power H2 Volume Growth?
by Swati Prasad
ILUMA's broader launch and expanded consumables range are contributing to PM's heated tobacco growth in 2025.
Is on! Brand Growth Enough to Offset MST Declines at Altria?
by Zacks Equity Research
MO's on! sales jump in the second quarter, but MST declines and pouch share losses raise questions about sustaining growth.
MO Expands Smoke-Free Portfolio: Can It Offset Combustible Declines?
by Zacks Equity Research
Altria's on! nicotine pouch shipments surge 26.5% in the second quarter, but can smoke-free gains offset cigarette declines?
VEEV Volumes Double: Will Philip Morris' E-Vapor Bet Pay Off?
by Swati Prasad
PM's VEEV shipments have more than doubled in the second quarter, with Europe driving growth and new markets showing early promise.